FindTrial
Sign In

Tanezumab 2.5 mg

BIOLOGICAL3 trials

Sponsors

Pfizer

Conditions

Chronic PainOsteoarthritis, HipOsteoarthritis, Knee

Phase 2

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections
TerminatedNCT00994890
PfizerOsteoarthritis, Hip, Osteoarthritis, Knee
Start: 2009-11-17End: 2011-03-01Updated: 2021-05-13

Phase 3

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
CompletedNCT02528188
PfizerChronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
Start: 2015-07-21End: 2019-02-27Updated: 2020-01-10
Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee
CompletedNCT02697773
PfizerOsteoarthritis, Hip, Osteoarthritis, Knee
Start: 2016-01-21End: 2018-05-14Updated: 2021-05-03

Related Papers

Effect size varies based on calculation method and may affect interpretation of treatment effect: an illustration using randomised clinical trials in osteoarthritis
Advances in Rheumatology2024-04-221 citations
Meaningful within-patient change for clinical outcome assessments: model-based approach versus cumulative distribution functions.
2023-11-205 citations
Characterization of adverse joint outcomes in patients with osteoarthritis treated with subcutaneous tanezumab
Osteoarthritis and Cartilage2023-08-2921 citations
Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor
CPT Pharmacometrics & Systems Pharmacology2023-07-201 citations
Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis.
2023-07-183 citations
Examining the Relationships Among Treatment, Pain, and Physical Function in Patients With Osteoarthritis
Clinical Journal of Pain2023-02-072 citations
Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical Trials
Clinical Pharmacology & Therapeutics2023-01-0913 citations
A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis.
2022-10-272 citations
Inter-Reader Consistency and Exclusionary Findings During Radiographic Screening for Phase 3 Trials of Tanezumab in Patients With Osteoarthritis.
2022-09-012 citations
Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials
Current Medical Research and Opinion2022-08-186 citations
Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis.
2022-08-12
Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab.
2022-07-022 citations
Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies.
2022-05-102 citations
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study
Arthritis Research & Therapy2022-03-2924 citations
WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee
The Journal of Rheumatology2022-03-0123 citations
Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis.
2022-02-144 citations
Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis.
2022-02-012 citations
Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo‐controlled trials
International Journal of Clinical Practice2021-10-093 citations
Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis.
2021-10-042 citations
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
Annals of the Rheumatic Diseases2020-06-01153 citations

5 more papers not shown